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Randomised trial of four-drug vs less intensive two-drug chemotherapy in
the palliative treatment ofpatients with small-cell lung cancer (SCLC) and
poor prognosis
Medical Research Council Lung Cancer Working Party* (prepared on behalf of the working party and its collaborators by NM
Bleehen, DJ Girling, P Hopwood, G Lallemand, D Machin, RJ Stephens and AJ Bailey)
Summary This randomised trial was conducted to compare a four-drug chemotherapy regimen as a control vs
a less intensive two-drug regimen in terms ofquality oflife (QL), tumour response and survival in the palliative
treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. A total of 310 patients with
extensive SCLC or limited disease but poor performance status were allocated at random to two chemotherapy
regimens, each given on 3 consecutive days at 3 week intervals for three cycles: etoposide, cyclophosphamide,
methotrexate and vincristine (ECMV, 154 patients) or etoposide and vincristine (EV, 156 patients). QL was
assessed by patients using the Rotterdam Symptom Checklist, the Hospital Anxiety and Depression Scale and a
daily diary card. Specific disease- and treatment-related symptoms were recorded by clinicians. The levels of
palliation were high and similar in the two groups, although the ECMV regimen was on balance superior in
palliating physical symptoms and reducing psychological distress. The EV regimen caused less toxicity,
particularly mucositis, which, using Kaplan Meier curves, occurred in an estimated 34% ofpatients compared
with 54% in the ECMV group. The estimated rates of WHO grade 2 or worse haematological toxicity were
21% in the EV compared with 38% in the ECMV patients. There was no overall difference in response or
survival; the median survival periods were 141 days in the ECMV group and 137 in the EV group and the
survival rates 37% and 38% at 6 months and 12% and 10% at 1 year respectively. Nevertheless, 37 ECMV
patients died within 3 weeks of starting the first cycle of chemotherapy (24 of them during the 2nd week)
compared with 18 (9) EV patients. The EV regimen is a useful palliative regimen for patients with SCLC and
poor prognosis.
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In patients with small-cell lung cancer (SCLC) and poor
prognosis, that is, with either extensive, metastatic disease or
with limited disease but poor performance status, the primary
aims of treatment should be to palliate symptoms and to
keep the patient well, active and out ofhospital for as long as
possible. The role of anti-cancer chemotherapy, particularly
the more aggressive regimens, in this group of patients is not
clear (Hansen, 1992). Some clinicians argue that there is little
justification for inflicting intensive, toxic treatment on ill and
frail patients with poor prognosis; treatment that could last
for a substantial proportion of their remaining survival
period. The present trial was therefore designed to compare,
in this patient group, a four-drug chemotherapy regimen as a
control vs a less intensive two-drug regimen in terms of
quality of life (QL), tumour response and survival.
The control regimen chosen was the combination of
etoposide, cyclophosphamide, methotrexate and vincristine
(ECMV). This regimen has been used extensively in Medical
Research Council (MRC) Lung Cancer Working Party trials.
It has the advantages that it can be widely applied and can be
administered on a largely outpatient basis. Large randomised
trials have shown that it is highly active against SCLC, and
that three cycles improve QL by providing excellent palliation
of symptoms (MRC Lung Cancer Working Party 1989a,b,
1993a; Fayers et al., 1991). Nevertheless, it is associated with
serious adverse effects, including probable treatment-related
death in around 5% of patients (Stephens et al., 1994).
The two-drug regimen of etoposide and vincristine was
chosen in the hope that it would provide as good palliation
as the control regimen, with less toxicity and hence improved
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QL, without compromising survival. In a non-randomised
study of 28 patients with extensive disease and two with
limited disease but considered unfit for more intensive
chemotherapy, this two-drug combination given in 3 week
cycles had been reported to provide a total response rate of
70% with less toxicity than other regimens of similar efficacy
(Morgan et al., 1987).
An important feature of the present trial is its inclusion of
multidimensional QL end points in a randomised comparison
of palliative treatment regimens.
Methods
Eligibility
Patients of either sex aged 80 years or less were eligible for
the trial if they had previously untreated histologically or
cytologically confirmed SCLC. Those with disease of limited
extent (MRC Lung Cancer Working Party, 1993a) had to
have poor (grade 3 or 4) performance status (World Health
Organization, 1979) (see Table I). Those with extensive
disease were eligible whatever their performance status. All
patients had to have normal renal function, no major
disturbance of liver function (plasma bilirubin concentration
not higher than twice the upper limit of the normal range for
the local laboratory), and no other previous or concomitant
malignant disease except basal cell carcinoma or in situ
carcinoma of the cervix. Patients were not eligible ifthey had
any disease contraindicating the chemotherapy regimens.
Local ethics committee approval of the protocol and
individual patient consent were required.
Microscopic diagnosis
The diagnosis was made by the histopathologist from the
referring centre according to the WHO classification (World
Health Organization, 1981). The slides were later examined
by a single reference histopathologist for confirmation of the
cell type.Table I Characteristics of the 310 patients pretreatment
ECMV EV Total
Characteristic No. % No. % No. (%)
Sex
Male 97 (63) 98 (63) 195 (63)
Female 57 (37) 58 (37) 115 (37)
Age (years):
<60 39 (25) 40 (26) 79 (25)
60-64 38 (25) 31 (20) 69 (22)
65-69 35 (23) 46 (29) 81 (26)
70-80 42 (27) 39 (25) 81 (26)
Overall condition
0 Excellent 2 (1) 5 (3) 7 (2)
1 Good 32 (21) 25 (16) 57 (19)
2 Fair 64 (42) 53 (34) 117 (38)
3 Poor 51 (34) 68 (44) 119 (39)
4 Very poor 2 (1) 4 (3) 6 (2)
Not known 3 1 4
Extent of disease,
Performance statusa
Limited
0-2 0 (0) 0 (0) 0 (0)
3 40 (26) 43 (28) 83 (27)
4 3 (2) 3 (2) 6 (2)
Extensive
0 6 (4) 6 (4) 12 (4)
1 31 (20) 29 (19) 60 (19)
2 37 (24) 37 (24) 74 (24)
3 36 (23) 35 (22) 71 (23)
4 1 (1) 3 (2) 4 (1)
ao, normal without restriction; 1, strenuous activity restricted,
ambulatory, can do light work; 2, up and about >50% of waking
hours, unable to work, capable of all self-care; 3, confined to bed or
chair >50% ofwaking hours, limited self-care; 4, confined to bed or
chair, no self-care, completely disabled.
Treatment allocation
Patients were randomly allocated by telephoning the MRC
Cancer Trials Office to one of the two treatment regimens
using a minimisation procedure, stratifying for the respon-
sible clinician, the extent of disease and the WHO
performance status, with separate categories for patients
with a datum unknown at time of randomisation (all missing
data subsequently became available).
ECMV The ECMV regimen comprised three cycles of
chemotherapy, each cycle given on 3 consecutive days at 3
week intervals. On day 1, etoposide 120 mg m-2 was given by
i.v. infusion over 30 min, together with cyclophosphamide
1 g m-2, methotrexate 35 mg m-2 and vincristine 1.3 mg m-2
(maximum 2.0 mg) by i.v. bolus injection. On days 2 and 3
etoposide was given in a dosage of either 240 mg m-2 by
mouth or 120 mg m-2 i.v.
EV The EV regimen comprised three cycles of etoposide
and vincristine given in the same dosages and schedule as for
the ECMV regimen.
Thoracic radiotherapy was not given as a routine to either
treatment group.
Reports and investigations
The pretreatment assessment included clinical examination, a
postero-anterior chest radiograph, measurement of the blood
haemoglobin and the plasma urea, creatinine, bilirubin,
albumin, electrolyte, aminotransferase and alkaline phospha-
tase concentrations and total white blood cell and platelet
counts. The extent of disease (limited or extensive), was
assessed on clinical and radiographic evidence.
A report was also completed at each attendance for
treatment, then monthly to 6 months from randomisation,
then once every 2 months to 1 year, and then once every 3
months. These reports included details ofthe treatment given,
the response to treatment (World Health Organization, 1979),
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any adverse reactions, the blood haemoglobin concentration
and total white cell and platelet counts. At death, the certified
cause was reported.
Assessment of QL
At each assessment, clinicians recorded the occurrence and
severity of 13 specified symptoms, WHO performance status
and overall condition, and patients completed a Rotterdam
Symptom Checklist (RSCL) (De Haes et al., 1990), to which
questions on chest pain, cough, difficulty swallowing and
coughing up blood had been added, recording their overall
experience (not at all, a little, moderately, very much) of each
symptom during the previous week. (They also completed a
Hospital Anxiety and Depression Scale (HADS) (Zigmond
and Snaith, 1983), but results from these will be reported
elsewhere.) The results from the RSCL questionnaires have
been used in the analysis of palliation, activities of daily
living and psychological distress. Data recorded by clinicians,
and corresponding laboratory data, have been used in the
analaysis of adverse reactions.
In addition, for the first 2 months in the trial, patients
were asked to complete an MRC patient diary card (Fayers
et al., 1991) every evening after their last meal, recording how
they had been feeling during the previous 24 h. They coded
their assessments of eight key physical symptoms using the
same four-point scale as in the RSCL. The purpose of these
cards was to obtain the patient's own daily assessment during
the treatment period, when these symptoms were likely to be
changing substantially from day to day.
Statistical methods
It was considered that a reduction in survival of more than
15% would not be acceptable in the EV group compared
with the ECMV group, even if this was associated with fewer
adverse effects. With 15% set as the equivalence level, and a
one-sided significance test of 5% and power 80%, the
required number of deaths is 264 (Machin and Campbell,
1987). An intake of 300 patients was therefore planned.
Response (World Health Organization, 1979) was assessed
from clinical and radiographic findings during the period up
to the time the first assessment after the third cycle of
chemotherapy was due. Patients who died during this period
were classified as non-responders.
Survival was calculated from the date of randomisation
until death, survivors being censored at date last known to be
alive. The Kaplan-Meier estimate was used to calculate
survival curves and the Mantel-Cox version of the log-rank
test to make treatment comparisons. Associated confidence
intervals (CIs) were calculated for the corresponding hazard
ratios (HRs).
Compliance in the use of the RSCLs was defined as
described by Hopwood et al. (1994), and was expressed as the
percentage ofexpected questionnaires received during the first
3 months. The expected number of questionnaires at each
protocol time point was the total number of patients then
alive; thus, no allowances were made for non-completion of
forms by terminally ill patients. The received numbers of
questionnaires were those which were at least 75% completed
within a time window around each time point. The windows
were -7 to + 1 days of start of treatment, -6 to + 14 at 3
and 6 weeks from randomisation, and -14 to + 14 at 3
months from randomisation. Compliance in the use of the
patient diary clrds was expressed as the percentage of days in
the first 8 weeks, or to death if this was sooner, that each
patient completed these instruments.
Palliation was defined as disappearance of a symptom
present pretreatment or improvement by one or more
categories in the first 3 months. In view of the different
early survival experience of the two treatment groups,
palliation and adverse effects of treatment were analysed
using the log-rank method, the time that palliation or an
adverse effect was first reported being the event in these
analyses. The activities of daily living were scored from thePalliative chemotherapy in SCLC
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relevant RSCL subscale. Patients record their ability to care
for themselves, walk about the house, do light housework/
household jobs, climb stairs, do heavy housework/household
jobs, walk out of doors and go shopping, under the
categories unable, only with help, with difficulty, and able.
A summary score is obtained by adding the scores (0=able
to 3 =unable) for each activity. These scores are displayed as
medians and as interquartile and total ranges. Psychological
distress is similarly scored from the eight relevant symptoms
listed by De Haes et al. (1990) (irritability, worrying,
depressed mood, nervousness, despondent feelings about the
future, feeling tense, anxious feelings, difficulty concentrat-
ing), plus restlessness, which subsequent factor analysis
showed to be relevant (Frith, 1992). The cut-off score of 11
based on eight symptoms (De Haes et al., 1990) for clinically
significant distress was therefore raised to 12.
In drawing up the daily profiles from the diary cards (see
Figure 3), adjustment was made for delays in giving some
cycles of chemotherapy by realigning the profiles to the
protocol schedule.
The trial data were managed using the COMPACT
program (COMPACT Steering Committee, 1991).
Results
Patients in the trial
Between November 1989 and September 1992, 310 patients
(154 ECMV, 156 EV) were admitted from 23 centres in the
UK. Their pretreatment characteristics are shown in Table I.
Overall condition was fair, poor or very poor in 79% of the
patients. Disease was limited in only 29%, and almost half
(48%) had both extensive disease and performance status 2
or worse. The distributions of these variables were similar in
the two treatment groups.
After randomisation, the pretreatment characteristics of
four patients (three ECMV, one EV) were revised locally,
making them ineligible; two (one ECMV, one EV) were
found to have no evidence of cancer, one had squamous
carcinoma, and one limited disease and good performance
status. All have been included in the following analyses,
which were conducted on the intention-to-treat principle.
The reference histopathologist assessed the diagnosis of
282 patients. Among the remaining 28, no slides were
received for 17, and the material was impossible to assess
in 11 (Thomas et al., 1993). He confirmed the diagnosis of
SCLC in 267 (95%) of the 282 patients assessed. In the
remaining 15 his diagnosis was undifferentiated in 11,
carcinoid in two, and squamous in two.
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Figure 1 Median scores of activities of daily living during the
first 3 months from randomisation obtained from the subscale of
the Rotterdam Symptom Checklist. The boxes show interquartile
ranges (containing 50% of results) and the lines total ranges.
Protocol chemotherapy received
In all (Table II), 88 (56%) of the ECMV compared with 107
(69%) of the EV patients received all three cycles of
chemotherapy but for 14 and eight respectively, at least one
cycle was delayed for more than 7 days. A further 15 (10%)
ECMV and 16 (10%) EV patients received two cycles, 1 and
2 respectively, with the second cycle delayed, and a further 47
(31%) and 28 (18%) received only one cycle. The remaining
four (3%) and five (3%) patients received no chemotherapy.
Four ECMV and three EV patients had one drug withdrawn
because of toxicity, and six ECMV but no EV patients had
dosages halved.
The commonest single reason why chemotherapy was not
completed was death before the next cycle could be given.
Moreover, this occurred more frequently in the ECMV group
(47 patients) than in the EV group (22 patients).
Additional anti-cancer treatment
In all, 55 ECMV and 65 EV patients received treatment
additional to protocol treatment; 38 ECMV and 41 EV were
given thoracic radiotherapy, five and ten respectively, on
completion of their chemotherapy and the others on relapse.
The other sites irradiated were bone in six ECMV and 18 EV
patients, brain in nine and six, distant lymph nodes in four
and eight, skin in one and two, and liver and kidney, each in
one EV patient. A total of 16 ECMV and 20 EV patients
received additional chemotherapy for relapse.
Clinicians' andpatients' compliance in completing QL forms
and diary cards
During the first 3 months, 991 RSCL forms were expected
and 653 (66%) with >75% of items completed received. Of
the missing forms, 178 (18%) were missing, although the
clinicians' forms were completed at the appropriate times. An
additional 96 RSCLs were received, having been completed
outside the specified time windows, and on two occasions a
patient completed two questionnaires within a single time
window. RSCLs were received for 78% of the total occasions
when clinicians' reports were completed, whether or not
Table II Chemotherapy received and reasons why not completed
ECMV EV Total
Chemotherapy received No. (%) No. (%) No. (%)
All three cycles 88 (56) 107 (69) 195 (63)
Two cycles only 15 (10) 16 (10) 31 (10)
Reason
Died before 3rd cycle 7 (5) 2 (1) 9 (3)
Toxicity 4 (3) 5 (3) 9 (3)
Progressive disease 3 (2) 5 (3) 8 (3)
Patient refusal 1 (1) 2 (1) 3 (1)
Switched to radiotherapy 0 - 1 (1) 1 (0)
Cardiac failure 0 - 1 (1) 1 (0)
One cycle only 47 (31) 28 (18) 75 (24)
Reason
Died before 2nd cycle 39 (25) 19 (12) 58 (19)
Toxicity 6 (4) 2 (1) 8 (3)
Progressive disease 1 (1) 4 (3) 5 (2)
Too ill 0 - 2 (1) 2 (1)
Patient refusal 0 - 1 (1) 1 (0)
Diagnosis changed 1 (1) 0 - 1 (0)
No chemotherapy 4 (3) 5 (3) 9 (3)
Reason
Died before start 1 (1) 1 (1) 2 (1)
Given intensive treatment 1 (1) 0 - 1 (0)
Too ill 0 - 3 (2) 3 (1)
Patient refusal 1 (1) 0 - 1 (0)
Diagnosis changed 1 (1) 1 (1) 2 (1)
Total patients 154 (100) 156 (100) 310 (100)Palliative chemotherapy in SCLC
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within a window. There was no difference in compliance
between the treatment groups. Clinicians' compliance in
providing data on the 13 specified symptoms was 78% for the
ECMV group and 82% for the EV group. The percentage of
patient diary card data received for the first 8 weeks was 47%
in the ECMV group and 53% in the EV group.
Patients' assessments ofpalliation of symptoms
The levels of palliation (Table III) were on balance slightly
higher in the ECMV group, although the differences were
small. The levels for the eight commonest symptoms, ranked
by frequency, are shown in the Table. The two commonest
were general symptoms; tiredness and lack of energy. The
two disease-related symptoms to appear in the first eight were
shortness of breath and cough. The estimated levels of
palliation achieved by 3 months were substantial. For
example, lack of energy was reported by 119 ECMV and
110 EV patients pretreatment. By 1 month the estimated
proportions with palliation were 33% in both groups, by 2
months 49 and 48% and by 3 months 56 and 53%
respectively. Cough was well palliated by the ECMV
regimen but substantially less well by the EV regimen.
The other disease-related symptoms, not shown in the
Table, were chest pain and haemoptysis. Although chest pain
was reported by only 64 ECMV and 67 EV patients, and
haemoptysis by 29 and 33 respectively, they were well
palliated. By 3 months, the estimated levels of palliation
were 96% in the ECMV group and 89% in the EV group for
chest pain, and 100% and 91% for haemoptysis.
In the ECMV and EV groups respectively, the median
numbers of symptoms were 17 and 18 pretreatment (eight
and seven, moderate or severe), and 14 and 17 at 3 months
(five and seven).
Patients' assessments of activities ofdaily living
During the first 3 months, there was similar but modest
improvement in the activities of daily living scores in both
treatment groups. The median scores, with their interquartile
and total ranges, are shown in Figure 1. A patient able to do
all seven activities from which the score is derived would
score 0, and one unable to do any would score 21. At
baseline, in the ECMV group, the median score was 7 and
the interquartile range 3 to 13. The baseline findings in the
EV group were broadly similar. The median scores fell from
7 to 5 in the ECMV group during the 3 months, and from 9
to 7 in the EV group.
Patients' assessments ofpsychological distress
The percentages of patients with psychological distress
(RSCL score 12 or more) are shown in Figure 2. In both
treatment groups, 27% of the patients had distress
pretreatment. This was reduced more successfully in the
ECMV than in the EV group (P =0.08, x2 test, for the
comparison of change from baseline to cycle 2). In the
ECMV group, the level fell to a minimum of 7% at the time
of cycle 2, rising to 12% at 3 months. In the EV group, the
minimum was 18% at the time ofcycle 2, but at 3 months the
level had risen to 24%.
Patients' assessments using the diary card
There was evidence from the diary cards that palliation of
cough, chest pain, breathlessness and haemoptysis was similar
in the two treatment groups, but that the adverse effects of
chemotherapy were worse in the ECMV group. The daily
percentages of patients reporting symptoms of any severity
are shown in Figure 3. For anorexia, nausea, vomiting and
dysphagia, these proportions reflect the pattern ofchemother-
apy administration, rising for a period during and
immediately after a cycle. Anorexia and dysphagia and, to
a lesser extent, nausea and vomiting, affected higher
proportions of patients in the ECMV than in the EV
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Figure 2 Percentages of patients with psychological distress
(scores of 12 or more) from the Rotterdam Symptom Checklist
subscale.
Table m Palliation of commonest symptoms as reported by patients using the Rotterdam Symptom Checklist
No.ofpatients Estimated percentage ofpatients
with symptom with palliation by:
Symptom Regimen pretreatment 1 month 2 months 3 months HRa 95% CI
Tiredness ECMV 121 (28) (52) (58) 0.89-2.03
EV 109 (42) (57) (66) 1.35
Lack of energy ECMV 119 (33) (49) (56) 0.63-1.49
EV 110 (33) (48) (53) 0.97
Shortness of breath ECMV 116 (59) (73) (75) 0.60-1.26
EV 111 (52) (67) (71) 0.86
Cough ECMV 104 (58) (75) (81) 0.41-0.90
EV 108 (36) (60) (63) 0.61
Worrying ECMV 111 (42) (75) (82) 0.61 -1.30
EV 99 (48) (63) (76) 0.89
Lack of appetite ECMV 105 (49) (63) (81) 0.76-1.67
EV 93 (53) (74) (81) 1.12
Difficulty sleeping ECMV 107 (49) (79) (83) 0.50-1.11
EV 86 (48) (60) (70) 0.74
Anxious feelings ECMV 95 (44) (72) (80) 0.72-1.55
EV 97 (48) (70) (80) 1.06
aHR> 1.0 indicates an advantage to the EV regimen.
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group. The total proportions reporting anorexia were 94% in
the ECMV group compared with 82% in the EV group, the
corresponding results being 84% and 76% for nausea, 66%
and 51% for vomiting, and 58% and 56% for dysphagia
respectively. The daily proportions of patients with cough,
chest pain and breathlessness fell to similar extents in the two
treatment groups. The proportions with haemoptysis were
low throughout.
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Clinicians' assessments ofadverse reactions to treatment
All the main adverse reactions reported by clinicians during
the first 3 months were less common in the EV group than in
the ECMV group (Table IV) with the exception of alopecia,
which affected almost all patients. The largest difference was
in sore mouth/mucositis, which was reported in an estimated
54% of the ECMV patients compared with 34% of the EV
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Figure 3 Daily percentages of patients reporting symptoms to be present a little, moderately, or very much on their diary cards (ECMV,
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Table IV Main adverse reactions reported by clinicians during the first 3 months
Estimated
Adverse reaction percentage ofpatients EV HR 95% CI
Alopecia (90) (97) 1.02 0.77-1.35
Anorexia (48) (43) 1.14 0.75- 1.76
Nausea (61) (48) 1.43 0.98-2.09
Vomiting (51) (44) 1.23 0.82- 1.85
Dysphagia (38) (27) 1.42 0.86-2.34
Sore mouth/mucositis (54) (34) 1.99 1.30-3.05
Numbness (38) (35) 1.16 0.73- 1.85
Haematological WHO grade 2
or worse: (38) (21) 2.17 1.27-3.70
Anaemia (32) (19) 1.97 1.11-3.52
Leucopenia (16) (4) 4.18 1.65-10.58
Thrombocytopenia (4) (2) 2.30 0.46- 11.45
aHR> 1.0 indicates an advantage to the EV regimen.
patients. The patients' reports using the RSCL were
essentially similar (details not presented). Haematological
toxicity affected an estimated 38% in the ECMV group
compared with 21% in the EV group. Anaemia was the
commonest form, followed by leucopenia and thrombocyto-
penia.
Response to treatment
Response to treatment was assessable in 141 ECMV and 147
EV patients and was similar in the two groups. It was partial
in 58 (41%) and 68 (46%), and complete in 20 (14%) and 11
(7%) respectively, giving overall response rates of 55% in the
ECMV group and 54% in the EV groups.
Survival
All but 5 of the 310 patients have died, and the five survivors
have been followed up for between 22 and 42 months. The
survival comparison by regimen for all the patients is shown
in Figure 4. There was no overall difference (2 =0.015,
d.f.=1, P=0.9, HR 0.99; 95% CI 0.79-1.24). The median
survival periods were 141 days in the ECMV group and 137
days in the EV group, and the survival rates were 37% and
38% at 6 months, and 12% and 10% at 12 months in the
two groups respectively. Nevertheless, there was a suggestion
of an increased risk of early death in the ECMV group, there
being 37 deaths within 3 weeks of starting chemotherapy in
the ECMV group compared with 18 in the EV group, of
which 24 and nine respectively, occurred during the 2nd
week, the period during which the white blood cell count was
likely to have been at its lowest.
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Figure 4 Percentage of patients surviving from date of
randomisation (life-table method).
The estimate of the HR was unaffected following separate
stratified analyses for the known prognostic factors:
performance status and extent of disease on admission.
Each had prognostic influence on survival, survival being
worse in patients with poor performance status and extensive
disease.
Cause ofdeath
Of the 152 ECMV patients who have died, 138 (91%) were
certified as having died from their cancer; in a further ten
(7%), toxicity was recorded as a major contributory cause,
and in the remaining four the cause was unrelated to the
cancer or its treatment. The corresponding figures for the 153
EV patients were cancer in 148 (97%), toxicity in two (1%),
and an unrelated cause in three.
Discussion
This randomised trial, involving 310 patients with SCLC and
poor prognosis, has shown that three cycles ofchemotherapy
with etoposide and vincristine (EV) is a useful palliative
regimen for patients too ill, or with disease too extensive, for
more intensive chemotherapy aimed primarily at prolonging
survival. The EV regimen was compared against a four-drug
control regimen of etoposide, cyclophosphamide, methotrex-
ate and vincristine (ECMV).
The usual end points of response, survival and toxicity are
insufficient for evaluating palliative treatment. The present
trial therefore also included assessments of other aspects of
quality oflife (QL), namely, palliation of symptoms, activities
of daily living, and psychological distress.
To what extent do the QL data influence our conclusions
from the comparison? Do all the QL domains favour one
regimen? If they did, the answer would be clear. In the event,
the picture was not so simple; the ECMV regimen was
slightly superior in palliating some of the physical symptoms
and in reducing psychological distress (the two may not be
unrelated, and this will be explored in a future paper); but it
involved a greater risk of early death and increased toxicity
(Table V).
Table V Summary of the balance of the clinical advantages and
disadvantages of the regimens compared
Endpoint Preferred regimen
QL
Palliation of symptoms ECMV
Activities of daily living Neither
Relief of psychological distress ECMV
Adverse effects of treatment EV
Response Neither
Overall survival Neither
Risk of early treatment-related death EV
Additional treatment ECMVPalliative chemotherapy in SCLC
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As recorded by patients using the Rotterdam Symptom
Checklist (RSCL), to which had been added symptoms
specifically related to lung cancer, the commonest symptoms
pretreatment tended to be general symptoms such as tiredness
and lack of energy. Only two cancer-related symptoms,
shortness of breath and cough, appeared in the eight
commonest. It is of considerable interest that in a concurrent
trial involving patients with non-small-cell lung cancer and
good performance status, the commonest symptoms were
essentially the same as those in the present trial (Hopwood et
al., 1995). It is important to appreciate the contribution that
general symptoms and those of psychological distress can
make to patients' QL, and the need to include them in
analyses of palliation.
Patients' activities of daily living are an important aspect
of their QL. The RSCL score is based on self-care, household
activities and ability to get out and about. Pretreatment, the
scores covered the entire range in both treatment groups.
Subsequently, median scores improved in both groups to a
similar extent.
Psychological distress, as assessed from the RSCL, was
relieved to a considerable degree in the ECMV group but
much less so in the EV group. Distress was prevalent in a
substantial minority of patients at any time point, and should
alert clinicians to the possibility that some patients may
warrant further assessment or support. A reassuring finding is
that the majority of patients appeared to enjoy normal
mental health, despite their illness and poor prognosis, and
that chemotherapy reduced psychological distress.
Patients were asked to complete a daily diary card on
physical symptoms for their first 2 months in the trial. The
daily proportions of patients reporting disease-related
symptoms, including cough, fell to similar extents in the
two treatment groups. The treatment-related symptoms,
dysphagia, nausea and vomiting, affected somewhat higher
proportions of patients in the ECMV than the EV group.
Other adverse reactions to treatment as reported by the
clinicians, notably sore mouth and haematological toxicity,
were substantially commoner in the ECMV group.
The above findings emphasise the importance of keeping
the various QL domains distinct in making comparisons
between treatment policies.
A potential weakness of basing treatment comparisons on
data from QL instruments completed by patients is the low
level of compliance in multicentre trials. Nevertheless, it is
generally agreed that, when possible, it is desirable to obtain
data from patients themselves rather than from surrogates
(Slevin et al., 1988; Stephens, 1994). Also, although clinicians
tend to underestimate the severity of symptoms compared
with patients themselves, estimates of differences between
treatment regimens are very similar whether clinicians' or
patients' assessments are used (Stephens, 1994). Compliance
by patients in completing questionnaires has been found to be
better when they are closely supervised, their performance
status is relatively good and they are receiving active therapy
(Ganz et al., 1988; Earl et al., 1991; MRC Lung Cancer
Working Party, 1993b). In current trials, the MRC Lung
Cancer Working Party is trying to improve compliance in a
number of ways, for example by giving patients a leaflet
explaining why QL data are important in making treatment
decisions.
At present, given the rapid attrition in lung cancer trials
and the rather low levels of compliance in completing
questionnaires, there is no entirely reliable way of analysing
data longitudinally. In this report, we adopted a novel
method of comparing palliation and adverse reactions using
Kaplan-Meier plots. The main advantage of this method is
that patients with missing data contribute; the main
disadvantages are, first, that censored patients (those who
did not achieve the event; start of palliation or start of an
adverse effect) are assumed to follow the same pattern as the
rest of the group, and secondly, that the duration and degree
of palliation or of adverse effects are not addressed. We need
to examine data in a number of ways to feel confident in our
conclusions.
It is desirable to achieve good palliation and minimal
toxicity without compromising survival. In the present trial,
survival was certainly no worse in the EV group. Indeed, the
risks of early death (within 3 weeks of the start of the first
cycle ofchemotherapy) were higher in the ECMV group. It is
likely that treatment was a contributory cause in many of
these early deaths. It is essential to keep the risk of early
death to a minimum. For patients and their families, there is
a profound difference between dying after a period (even a
short period) of good palliation and improved QL and dying
within a few days of starting treatment intended to achieve
these goals. We have analysed the distribution ofearly deaths
in 2196 patients in six MRC small-cell lung cancer trials
(Stephens et al., 1994). This analysis showed that they were
clustered in the 2nd week after the start of the first cycle of a
chemotherapy regimen, the period when the peripheral white
blood cell count is likely to have been at its lowest.
Moreover, two pretreatment variables associated with
increased risk of early death were a raised white blood cell
count and poor performance status. These findings suggest
that latent infection could be a contributory cause, and that
routine use of prophylactic antibiotics immediately before
and during chemotherapy might help to prevent them
(Morritu et al., 1989). Prophylactic antibiotics were not
recommended as routine in the present trial and randomised
comparisons are needed to explore whether the risks of early
death, particularly in patients at high risk, can be reduced by
their use.
Both regimens of the present trial proved to be acceptable
to patients. More than 60% received all three cycles and the
commonest reason why chemotherapy was not completed
was death before the next cycle could be given. It is
important to ensure that chemotherapy given late in their
survival period is of genuine benefit to patients. Somewhat
more patients in the EV group required further specific anti-
cancer treatment; in both groups, most of this was
radiotherapy to thoracic or metastatic sites.
For clinicians in discussing the advantages and disadvan-
tages of various treatment policies with their patients, this
trial clearly illustrates the relevance of QL end points in
addition to those of response and survival. Differences
between regimens are not always so clear-cut that the choice
between them is obvious; more often, some sort of trade-off
between potential benefits, adverse effects and risks has to be
made. To discuss these issues with their patients, clinicians
need reliable information from randomised comparisons.
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